English

Vir Biotechnology, Inc.

EDGAR

VIR Current report (8-K) · filed 2026-10-28

Annual consolidated revenue for 2025: about USD 68.56M, using the latest reported figures. The previous period, 2024, was about USD 74.21M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

239 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 238946000 USD Source

Operating margin

30.75%

2026 Q2 · %

Exact inputs and evidence

Operating Income: 73467000 USD Source
Revenue: 238946000 USD Source

Operating cash flow

123 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -9060000 USD Source
Operating Cash Flow: -132386000 USD Source

Free cash flow

123 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -9060000 USD Source
Operating Cash Flow: -132386000 USD Source
Capital Expenditure: 422000 USD Source
Capital Expenditure: 390000 USD Source

Cash and cash equivalents: 279 million USD 2026-06-30 Source
Exact value

278729000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 169 million shares 2026-06-30 Source
Exact value

169185671 shares

Reported share-count change

21.82% · 30.3 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

138886274 shares · 2025-06-30· Source
169185671 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

303 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 240000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 68556000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 4486000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: -29000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 238946000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-252 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -163141000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -437987000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -395064000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -125695000 USD · 2026-01-01 – 2026-03-31 Source
Net income: 80080000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-203 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -365905000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -198335000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -391781000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -365905000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -132386000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -9060000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -132386000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

1.09 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 4484000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 4167000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 4832000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 4484000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 390000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 422000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 390000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-204 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -365905000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -198335000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -391781000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -365905000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -132386000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -9060000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -132386000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 4484000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 4167000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 4832000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 4484000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 390000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 422000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 390000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-28.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2025-12-31
Operating income: 9 of 11 periods available· newest 2025-12-31
Net income: 9 of 11 periods available· newest 2025-12-31
Operating cash flow: 9 of 11 periods available· newest 2025-12-31
Capital expenditure: 9 of 11 periods available· newest 2025-12-31
Total assets: 8 of 11 periods available· newest 2025-12-31
Total liabilities: 8 of 11 periods available· newest 2025-12-31
Current assets: 8 of 11 periods available· newest 2025-12-31
Current liabilities: 8 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 8 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-7.6%

Prior period

USD 74.21 million

2024-01-01 – 2024-12-31
Current period

USD 68.56 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

68556000 − 74205000 = -5649000 USD

74205000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
68556000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Vir Biotechnology, Inc. · 2025-12-31 Vir Biotechnology, Inc. (edgar:1706431) Year-over-year change in Revenue: -5649000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 68556000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1883204 Filing: 000162828026010749 Input fundies:Revenue: 74205000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1884177 Filing: 000162828026010749
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 83.97 million

Prior period

−USD 521.96 million

2024-01-01 – 2024-12-31
Current period

−USD 437.99 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-437987000 − -521960000 = 83973000 USD

-521960000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-437987000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Vir Biotechnology, Inc. · 2025-12-31 Vir Biotechnology, Inc. (edgar:1706431) Year-over-year change in Net income: 83973000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -437987000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1699446 Filing: 000162828026010749 Input fundies:NetIncome: -521960000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1700296 Filing: 000162828026010749
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 54.57 million

Prior period

−USD 446.35 million

2024-01-01 – 2024-12-31
Current period

−USD 391.78 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-391781000 − -446352000 = 54571000 USD

-446352000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-391781000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Vir Biotechnology, Inc. · 2025-12-31 Vir Biotechnology, Inc. (edgar:1706431) Year-over-year change in Operating cash flow: 54571000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -391781000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1197034 Filing: 000162828026010749 Input fundies:OperatingCashFlow: -446352000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1197686 Filing: 000162828026010749
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-33.8%

Prior period

USD 7.3 million

2024-01-01 – 2024-12-31
Current period

USD 4.83 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

4832000 − 7301000 = -2469000 USD

7301000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
4832000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Vir Biotechnology, Inc. · 2025-12-31 Vir Biotechnology, Inc. (edgar:1706431) Year-over-year change in Capital expenditure: -2469000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 4832000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1201710 Filing: 000162828026010749 Input fundies:CapitalExpenditure: 7301000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1202299 Filing: 000162828026010749
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 68.56 million 100% of revenue
Cost of revenue USD 26,000 0% of revenue
Operating expenses USD 548.04 million 799% of revenue
Operating income −USD 479.33 million −699% of revenue
Tax, interest and other Derived −USD 41.34 million −60% of revenue
Net income −USD 437.99 million −639% of revenue

Cash

Operating cash flow −USD 391.78 million −571% of revenue
Capital expenditure USD 4.83 million 7% of revenue
Free cash flow Derived −USD 396.61 million −579% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 Operating loss: operating costs were 3,109% of revenue.
2018 Operating loss: operating costs were 1,213% of revenue.
2019 Operating loss: operating costs were 2,300% of revenue.
2020 Operating loss: operating costs were 489% of revenue.
2021 Net income was higher than operating income, so the split is not drawn.
2022 32%20%48%
2023 Operating loss: operating costs were 894% of revenue.
2024 Operating loss: operating costs were 891% of revenue.
2025 Operating loss: operating costs were 799% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2017-01-01 – 2017-12-31	2708000	84205000 Derived	-81497000	-11645000 Derived	-69852000	-69123000 Derived	Source 2017-01-01 – 2017-12-31: 2708000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -81497000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -69852000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -66381000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 2742000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	10668000	129360000 Derived	-118692000	-2808000 Derived	-115884000	-102288000 Derived	Source 2018-01-01 – 2018-12-31: 10668000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -118692000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -115884000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -94096000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 8192000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	8091000	186070000 Derived	-177979000	-3296000 Derived	-174683000	-138572000 Derived	Source 2019-01-01 – 2019-12-31: 8091000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -177979000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -174683000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -129632000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 8940000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	76368000	373348000 Derived	-296980000	1685000 Derived	-298665000	-197490000 Derived	Source 2020-01-01 – 2020-12-31: 76368000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -296980000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -298665000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -190941000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 6549000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	1095415000	674664000 Derived	420751000	-107833000 Derived	528584000	-69406000 Derived	Source 2021-01-01 – 2021-12-31: 1095415000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 420751000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 528584000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -47589000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 21817000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	1615797000	782729000 Derived	833068000	317231000 Derived	515837000	1595247000 Derived	Source 2022-01-01 – 2022-12-31: 1615797000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: 833068000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: 515837000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: 1663253000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 68006000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	86180000	770485000 Derived	-684305000	-69244000 Derived	-615061000	-800358000 Derived	Source 2023-01-01 – 2023-12-31: 86180000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -684305000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -615061000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -778785000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 21573000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	74205000	661370000 Derived	-587165000	-65205000 Derived	-521960000	-453653000 Derived	Source 2024-01-01 – 2024-12-31: 74205000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -587165000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -521960000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -446352000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 7301000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	68556000	547884000 Derived	-479328000	-41341000 Derived	-437987000	-396613000 Derived	Source 2025-01-01 – 2025-12-31: 68556000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -479328000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -437987000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -391781000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 4832000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 68.6M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Revenue	2708000	Revenue: 2708000 Open source
20182018-12-31	Revenue	10668000	Revenue: 10668000 Open source
20192019-12-31	Revenue	8091000	Revenue: 8091000 Open source
20202020-12-31	Revenue	76368000	Revenue: 76368000 Open source
20212021-12-31	Revenue	1095415000	Revenue: 1095415000 Open source
20222022-12-31	Revenue	1615797000	Revenue: 1615797000 Open source
20232023-12-31	Revenue	86180000	Revenue: 86180000 Open source
20242024-12-31	Revenue	74205000	Revenue: 74205000 Open source
20252025-12-31	Revenue	68556000	Revenue: 68556000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-7.6% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Year over year	No prior comparable period	Revenue: 2708000 Open source
20182018-12-31	Year over year	293.9%	Revenue: 10668000 Open source Revenue: 2708000 Open source
20192019-12-31	Year over year	-24.2%	Revenue: 8091000 Open source Revenue: 10668000 Open source
20202020-12-31	Year over year	843.9%	Revenue: 76368000 Open source Revenue: 8091000 Open source
20212021-12-31	Year over year	1,334.4%	Revenue: 1095415000 Open source Revenue: 76368000 Open source
20222022-12-31	Year over year	47.5%	Revenue: 1615797000 Open source Revenue: 1095415000 Open source
20232023-12-31	Year over year	-94.7%	Revenue: 86180000 Open source Revenue: 1615797000 Open source
20242024-12-31	Year over year	-13.9%	Revenue: 74205000 Open source Revenue: 86180000 Open source
20252025-12-31	Year over year	-7.6%	Revenue: 68556000 Open source Revenue: 74205000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -699.2% 2025

Net margin -638.9% 2025

Free cash flow margin -578.5% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Operating margin	-3,009.5%	Operating Income: -81497000 Open source Revenue: 2708000 Open source
20182018-12-31	Operating margin	-1,112.6%	Operating Income: -118692000 Open source Revenue: 10668000 Open source
20192019-12-31	Operating margin	-2,199.7%	Operating Income: -177979000 Open source Revenue: 8091000 Open source
20202020-12-31	Operating margin	-388.9%	Operating Income: -296980000 Open source Revenue: 76368000 Open source
20212021-12-31	Operating margin	38.4%	Operating Income: 420751000 Open source Revenue: 1095415000 Open source
20222022-12-31	Operating margin	51.6%	Operating Income: 833068000 Open source Revenue: 1615797000 Open source
20232023-12-31	Operating margin	-794%	Operating Income: -684305000 Open source Revenue: 86180000 Open source
20242024-12-31	Operating margin	-791.3%	Operating Income: -587165000 Open source Revenue: 74205000 Open source
20252025-12-31	Operating margin	-699.2%	Operating Income: -479328000 Open source Revenue: 68556000 Open source
20172017-12-31	Net margin	-2,579.5%	Net Income: -69852000 Open source Revenue: 2708000 Open source
20182018-12-31	Net margin	-1,086.3%	Net Income: -115884000 Open source Revenue: 10668000 Open source
20192019-12-31	Net margin	-2,159%	Net Income: -174683000 Open source Revenue: 8091000 Open source
20202020-12-31	Net margin	-391.1%	Net Income: -298665000 Open source Revenue: 76368000 Open source
20212021-12-31	Net margin	48.3%	Net Income: 528584000 Open source Revenue: 1095415000 Open source
20222022-12-31	Net margin	31.9%	Net Income: 515837000 Open source Revenue: 1615797000 Open source
20232023-12-31	Net margin	-713.7%	Net Income: -615061000 Open source Revenue: 86180000 Open source
20242024-12-31	Net margin	-703.4%	Net Income: -521960000 Open source Revenue: 74205000 Open source
20252025-12-31	Net margin	-638.9%	Net Income: -437987000 Open source Revenue: 68556000 Open source
20172017-12-31	Free cash flow margin	-2,552.5%	Revenue: 2708000 Open source Operating Cash Flow: -66381000 Open source Capital Expenditure: 2742000 Open source
20182018-12-31	Free cash flow margin	-958.8%	Revenue: 10668000 Open source Operating Cash Flow: -94096000 Open source Capital Expenditure: 8192000 Open source
20192019-12-31	Free cash flow margin	-1,712.7%	Revenue: 8091000 Open source Operating Cash Flow: -129632000 Open source Capital Expenditure: 8940000 Open source
20202020-12-31	Free cash flow margin	-258.6%	Revenue: 76368000 Open source Operating Cash Flow: -190941000 Open source Capital Expenditure: 6549000 Open source
20212021-12-31	Free cash flow margin	-6.3%	Revenue: 1095415000 Open source Operating Cash Flow: -47589000 Open source Capital Expenditure: 21817000 Open source
20222022-12-31	Free cash flow margin	98.7%	Revenue: 1615797000 Open source Operating Cash Flow: 1663253000 Open source Capital Expenditure: 68006000 Open source
20232023-12-31	Free cash flow margin	-928.7%	Revenue: 86180000 Open source Operating Cash Flow: -778785000 Open source Capital Expenditure: 21573000 Open source
20242024-12-31	Free cash flow margin	-611.4%	Revenue: 74205000 Open source Operating Cash Flow: -446352000 Open source Capital Expenditure: 7301000 Open source
20252025-12-31	Free cash flow margin	-578.5%	Revenue: 68556000 Open source Operating Cash Flow: -391781000 Open source Capital Expenditure: 4832000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -391.8M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Operating cash flow	-66381000	Operating Cash Flow: -66381000 Open source
20182018-12-31	Operating cash flow	-94096000	Operating Cash Flow: -94096000 Open source
20192019-12-31	Operating cash flow	-129632000	Operating Cash Flow: -129632000 Open source
20202020-12-31	Operating cash flow	-190941000	Operating Cash Flow: -190941000 Open source
20212021-12-31	Operating cash flow	-47589000	Operating Cash Flow: -47589000 Open source
20222022-12-31	Operating cash flow	1663253000	Operating Cash Flow: 1663253000 Open source
20232023-12-31	Operating cash flow	-778785000	Operating Cash Flow: -778785000 Open source
20242024-12-31	Operating cash flow	-446352000	Operating Cash Flow: -446352000 Open source
20252025-12-31	Operating cash flow	-391781000	Operating Cash Flow: -391781000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -396.6M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Free cash flow	-69123000	Operating Cash Flow: -66381000 Open source Capital Expenditure: 2742000 Open source
20182018-12-31	Free cash flow	-102288000	Operating Cash Flow: -94096000 Open source Capital Expenditure: 8192000 Open source
20192019-12-31	Free cash flow	-138572000	Operating Cash Flow: -129632000 Open source Capital Expenditure: 8940000 Open source
20202020-12-31	Free cash flow	-197490000	Operating Cash Flow: -190941000 Open source Capital Expenditure: 6549000 Open source
20212021-12-31	Free cash flow	-69406000	Operating Cash Flow: -47589000 Open source Capital Expenditure: 21817000 Open source
20222022-12-31	Free cash flow	1595247000	Operating Cash Flow: 1663253000 Open source Capital Expenditure: 68006000 Open source
20232023-12-31	Free cash flow	-800358000	Operating Cash Flow: -778785000 Open source Capital Expenditure: 21573000 Open source
20242024-12-31	Free cash flow	-453653000	Operating Cash Flow: -446352000 Open source Capital Expenditure: 7301000 Open source
20252025-12-31	Free cash flow	-396613000	Operating Cash Flow: -391781000 Open source Capital Expenditure: 4832000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

23.7% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2017-12-31	Liabilities / assets	Not reported	No source recorded
20182018-12-31	Liabilities / assets	32.2%	Total Liabilities: 61636000 Open source Total Assets: 191596000 Open source
20192019-12-31	Liabilities / assets	17.2%	Total Liabilities: 88129000 Open source Total Assets: 512071000 Open source
20202020-12-31	Liabilities / assets	22%	Total Liabilities: 201909000 Open source Total Assets: 918761000 Open source
20212021-12-31	Liabilities / assets	26.7%	Total Liabilities: 522419000 Open source Total Assets: 1954268000 Open source
20222022-12-31	Liabilities / assets	25.8%	Total Liabilities: 724125000 Open source Total Assets: 2802088000 Open source
20232023-12-31	Liabilities / assets	17.1%	Total Liabilities: 328824000 Open source Total Assets: 1919060000 Open source
20242024-12-31	Liabilities / assets	17.8%	Total Liabilities: 248428000 Open source Total Assets: 1398813000 Open source
20252025-12-31	Liabilities / assets	23.7%	Total Liabilities: 237547000 Open source Total Assets: 1002823000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.54× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2017-12-31	Current assets / current liabilities	Not reported	No source recorded
20182018-12-31	Current assets / current liabilities	2.95×	Current Assets: 117783000 Open source Current Liabilities: 39908000 Open source
20192019-12-31	Current assets / current liabilities	6.81×	Current Assets: 402995000 Open source Current Liabilities: 59206000 Open source
20202020-12-31	Current assets / current liabilities	7.8×	Current Assets: 772365000 Open source Current Liabilities: 99064000 Open source
20212021-12-31	Current assets / current liabilities	4.58×	Current Assets: 1562821000 Open source Current Liabilities: 341242000 Open source
20222022-12-31	Current assets / current liabilities	4.93×	Current Assets: 2519077000 Open source Current Liabilities: 511029000 Open source
20232023-12-31	Current assets / current liabilities	9.05×	Current Assets: 1588226000 Open source Current Liabilities: 175407000 Open source
20242024-12-31	Current assets / current liabilities	8.71×	Current Assets: 1042458000 Open source Current Liabilities: 119662000 Open source
20252025-12-31	Current assets / current liabilities	5.54×	Current Assets: 514080000 Open source Current Liabilities: 92815000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2017-01-01 – 2017-12-31	−USD 69.85 million Exact value Exact value: -69852000 USD 2017-01-01 – 2017-12-31: -69852000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Vir Biotechnology, Inc. · 2017-12-31 Vir Biotechnology, Inc. (edgar:1706431) Net Income: -69852000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -69852000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-10k_20191231.htm#2228063 Filing: 000156459020013194 The citation records this snapshot. The page link may show a newer release later.	−USD 66.38 million Exact value Exact value: -66381000 USD 2017-01-01 – 2017-12-31: -66381000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vir Biotechnology, Inc. · 2017-12-31 Vir Biotechnology, Inc. (edgar:1706431) Operating Cash Flow: -66381000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -66381000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-10k_20191231.htm#2677744 Filing: 000156459020013194 The citation records this snapshot. The page link may show a newer release later.	USD 2.74 million Exact value Exact value: 2742000 USD 2017-01-01 – 2017-12-31: 2742000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vir Biotechnology, Inc. · 2017-12-31 Vir Biotechnology, Inc. (edgar:1706431) Capital Expenditure: 2742000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2742000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-10k_20191231.htm#2688875 Filing: 000156459020013194 The citation records this snapshot. The page link may show a newer release later.	−USD 69.12 million Calculation and evidence -66381000 − 2742000 USD Exact free cash flow: -69123000 USD 2017-01-01 – 2017-12-31: -66381000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 2742000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vir Biotechnology, Inc. · 2017-12-31 Vir Biotechnology, Inc. (edgar:1706431) Free cash flow: -69123000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -66381000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-10k_20191231.htm#2677744 Filing: 000156459020013194 Input fundies:CapitalExpenditure: 2742000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-10k_20191231.htm#2688875 Filing: 000156459020013194 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 115.88 million Exact value Exact value: -115884000 USD 2018-01-01 – 2018-12-31: -115884000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Vir Biotechnology, Inc. · 2018-12-31 Vir Biotechnology, Inc. (edgar:1706431) Net Income: -115884000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -115884000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-10k_20201231.htm#2386654 Filing: 000156459021008915 The citation records this snapshot. The page link may show a newer release later.	−USD 94.1 million Exact value Exact value: -94096000 USD 2018-01-01 – 2018-12-31: -94096000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vir Biotechnology, Inc. · 2018-12-31 Vir Biotechnology, Inc. (edgar:1706431) Operating Cash Flow: -94096000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -94096000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-10k_20201231.htm#2904502 Filing: 000156459021008915 The citation records this snapshot. The page link may show a newer release later.	USD 8.19 million Exact value Exact value: 8192000 USD 2018-01-01 – 2018-12-31: 8192000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vir Biotechnology, Inc. · 2018-12-31 Vir Biotechnology, Inc. (edgar:1706431) Capital Expenditure: 8192000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8192000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-10k_20201231.htm#2915685 Filing: 000156459021008915 The citation records this snapshot. The page link may show a newer release later.	−USD 102.29 million Calculation and evidence -94096000 − 8192000 USD Exact free cash flow: -102288000 USD 2018-01-01 – 2018-12-31: -94096000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 8192000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vir Biotechnology, Inc. · 2018-12-31 Vir Biotechnology, Inc. (edgar:1706431) Free cash flow: -102288000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -94096000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-10k_20201231.htm#2904502 Filing: 000156459021008915 Input fundies:CapitalExpenditure: 8192000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-10k_20201231.htm#2915685 Filing: 000156459021008915 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 174.68 million Exact value Exact value: -174683000 USD 2019-01-01 – 2019-12-31: -174683000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Vir Biotechnology, Inc. · 2019-12-31 Vir Biotechnology, Inc. (edgar:1706431) Net Income: -174683000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -174683000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000095017022002295/vir-20211231.htm#4236827 Filing: 000095017022002295 The citation records this snapshot. The page link may show a newer release later.	−USD 129.63 million Exact value Exact value: -129632000 USD 2019-01-01 – 2019-12-31: -129632000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vir Biotechnology, Inc. · 2019-12-31 Vir Biotechnology, Inc. (edgar:1706431) Operating Cash Flow: -129632000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -129632000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000095017022002295/vir-20211231.htm#2943348 Filing: 000095017022002295 The citation records this snapshot. The page link may show a newer release later.	USD 8.94 million Exact value Exact value: 8940000 USD 2019-01-01 – 2019-12-31: 8940000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vir Biotechnology, Inc. · 2019-12-31 Vir Biotechnology, Inc. (edgar:1706431) Capital Expenditure: 8940000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8940000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000095017022002295/vir-20211231.htm#2953650 Filing: 000095017022002295 The citation records this snapshot. The page link may show a newer release later.	−USD 138.57 million Calculation and evidence -129632000 − 8940000 USD Exact free cash flow: -138572000 USD 2019-01-01 – 2019-12-31: -129632000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 8940000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vir Biotechnology, Inc. · 2019-12-31 Vir Biotechnology, Inc. (edgar:1706431) Free cash flow: -138572000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -129632000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000095017022002295/vir-20211231.htm#2943348 Filing: 000095017022002295 Input fundies:CapitalExpenditure: 8940000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000095017022002295/vir-20211231.htm#2953650 Filing: 000095017022002295 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 298.67 million Exact value Exact value: -298665000 USD 2020-01-01 – 2020-12-31: -298665000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Vir Biotechnology, Inc. · 2020-12-31 Vir Biotechnology, Inc. (edgar:1706431) Net Income: -298665000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -298665000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000095017023005118/vir-20221231.htm#4344977 Filing: 000095017023005118 The citation records this snapshot. The page link may show a newer release later.	−USD 190.94 million Exact value Exact value: -190941000 USD 2020-01-01 – 2020-12-31: -190941000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vir Biotechnology, Inc. · 2020-12-31 Vir Biotechnology, Inc. (edgar:1706431) Operating Cash Flow: -190941000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -190941000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000095017023005118/vir-20221231.htm#2964812 Filing: 000095017023005118 The citation records this snapshot. The page link may show a newer release later.	USD 6.55 million Exact value Exact value: 6549000 USD 2020-01-01 – 2020-12-31: 6549000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vir Biotechnology, Inc. · 2020-12-31 Vir Biotechnology, Inc. (edgar:1706431) Capital Expenditure: 6549000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6549000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000095017023005118/vir-20221231.htm#2982617 Filing: 000095017023005118 The citation records this snapshot. The page link may show a newer release later.	−USD 197.49 million Calculation and evidence -190941000 − 6549000 USD Exact free cash flow: -197490000 USD 2020-01-01 – 2020-12-31: -190941000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 6549000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vir Biotechnology, Inc. · 2020-12-31 Vir Biotechnology, Inc. (edgar:1706431) Free cash flow: -197490000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -190941000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000095017023005118/vir-20221231.htm#2964812 Filing: 000095017023005118 Input fundies:CapitalExpenditure: 6549000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000095017023005118/vir-20221231.htm#2982617 Filing: 000095017023005118 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 528.58 million Exact value Exact value: 528584000 USD 2021-01-01 – 2021-12-31: 528584000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Vir Biotechnology, Inc. · 2021-12-31 Vir Biotechnology, Inc. (edgar:1706431) Net Income: 528584000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 528584000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828024006852/vir-20231231.htm#1361034 Filing: 000162828024006852 The citation records this snapshot. The page link may show a newer release later.	−USD 47.59 million Exact value Exact value: -47589000 USD 2021-01-01 – 2021-12-31: -47589000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vir Biotechnology, Inc. · 2021-12-31 Vir Biotechnology, Inc. (edgar:1706431) Operating Cash Flow: -47589000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -47589000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828024006852/vir-20231231.htm#1481089 Filing: 000162828024006852 The citation records this snapshot. The page link may show a newer release later.	USD 21.82 million Exact value Exact value: 21817000 USD 2021-01-01 – 2021-12-31: 21817000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vir Biotechnology, Inc. · 2021-12-31 Vir Biotechnology, Inc. (edgar:1706431) Capital Expenditure: 21817000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21817000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828024006852/vir-20231231.htm#1484038 Filing: 000162828024006852 The citation records this snapshot. The page link may show a newer release later.	−USD 69.41 million Calculation and evidence -47589000 − 21817000 USD Exact free cash flow: -69406000 USD 2021-01-01 – 2021-12-31: -47589000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 21817000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vir Biotechnology, Inc. · 2021-12-31 Vir Biotechnology, Inc. (edgar:1706431) Free cash flow: -69406000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -47589000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828024006852/vir-20231231.htm#1481089 Filing: 000162828024006852 Input fundies:CapitalExpenditure: 21817000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828024006852/vir-20231231.htm#1484038 Filing: 000162828024006852 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	USD 515.84 million Exact value Exact value: 515837000 USD 2022-01-01 – 2022-12-31: 515837000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Vir Biotechnology, Inc. · 2022-12-31 Vir Biotechnology, Inc. (edgar:1706431) Net Income: 515837000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: 515837000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828025008245/vir-20241231.htm#1767493 Filing: 000162828025008245 The citation records this snapshot. The page link may show a newer release later.	USD 1.66 billion Exact value Exact value: 1663253000 USD 2022-01-01 – 2022-12-31: 1663253000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vir Biotechnology, Inc. · 2022-12-31 Vir Biotechnology, Inc. (edgar:1706431) Operating Cash Flow: 1663253000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1663253000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828025008245/vir-20241231.htm#1248860 Filing: 000162828025008245 The citation records this snapshot. The page link may show a newer release later.	USD 68.01 million Exact value Exact value: 68006000 USD 2022-01-01 – 2022-12-31: 68006000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vir Biotechnology, Inc. · 2022-12-31 Vir Biotechnology, Inc. (edgar:1706431) Capital Expenditure: 68006000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 68006000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828025008245/vir-20241231.htm#1253609 Filing: 000162828025008245 The citation records this snapshot. The page link may show a newer release later.	USD 1.6 billion Calculation and evidence 1663253000 − 68006000 USD Exact free cash flow: 1595247000 USD 2022-01-01 – 2022-12-31: 1663253000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 68006000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vir Biotechnology, Inc. · 2022-12-31 Vir Biotechnology, Inc. (edgar:1706431) Free cash flow: 1595247000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1663253000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828025008245/vir-20241231.htm#1248860 Filing: 000162828025008245 Input fundies:CapitalExpenditure: 68006000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828025008245/vir-20241231.htm#1253609 Filing: 000162828025008245 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 615.06 million Exact value Exact value: -615061000 USD 2023-01-01 – 2023-12-31: -615061000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Vir Biotechnology, Inc. · 2023-12-31 Vir Biotechnology, Inc. (edgar:1706431) Net Income: -615061000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -615061000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1701147 Filing: 000162828026010749 The citation records this snapshot. The page link may show a newer release later.	−USD 778.79 million Exact value Exact value: -778785000 USD 2023-01-01 – 2023-12-31: -778785000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vir Biotechnology, Inc. · 2023-12-31 Vir Biotechnology, Inc. (edgar:1706431) Operating Cash Flow: -778785000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -778785000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1198339 Filing: 000162828026010749 The citation records this snapshot. The page link may show a newer release later.	USD 21.57 million Exact value Exact value: 21573000 USD 2023-01-01 – 2023-12-31: 21573000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vir Biotechnology, Inc. · 2023-12-31 Vir Biotechnology, Inc. (edgar:1706431) Capital Expenditure: 21573000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21573000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1202889 Filing: 000162828026010749 The citation records this snapshot. The page link may show a newer release later.	−USD 800.36 million Calculation and evidence -778785000 − 21573000 USD Exact free cash flow: -800358000 USD 2023-01-01 – 2023-12-31: -778785000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 21573000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vir Biotechnology, Inc. · 2023-12-31 Vir Biotechnology, Inc. (edgar:1706431) Free cash flow: -800358000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -778785000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1198339 Filing: 000162828026010749 Input fundies:CapitalExpenditure: 21573000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1202889 Filing: 000162828026010749 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 521.96 million Exact value Exact value: -521960000 USD 2024-01-01 – 2024-12-31: -521960000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Vir Biotechnology, Inc. · 2024-12-31 Vir Biotechnology, Inc. (edgar:1706431) Net Income: -521960000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -521960000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1700296 Filing: 000162828026010749 The citation records this snapshot. The page link may show a newer release later.	−USD 446.35 million Exact value Exact value: -446352000 USD 2024-01-01 – 2024-12-31: -446352000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vir Biotechnology, Inc. · 2024-12-31 Vir Biotechnology, Inc. (edgar:1706431) Operating Cash Flow: -446352000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -446352000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1197686 Filing: 000162828026010749 The citation records this snapshot. The page link may show a newer release later.	USD 7.3 million Exact value Exact value: 7301000 USD 2024-01-01 – 2024-12-31: 7301000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vir Biotechnology, Inc. · 2024-12-31 Vir Biotechnology, Inc. (edgar:1706431) Capital Expenditure: 7301000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7301000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1202299 Filing: 000162828026010749 The citation records this snapshot. The page link may show a newer release later.	−USD 453.65 million Calculation and evidence -446352000 − 7301000 USD Exact free cash flow: -453653000 USD 2024-01-01 – 2024-12-31: -446352000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 7301000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vir Biotechnology, Inc. · 2024-12-31 Vir Biotechnology, Inc. (edgar:1706431) Free cash flow: -453653000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -446352000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1197686 Filing: 000162828026010749 Input fundies:CapitalExpenditure: 7301000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1202299 Filing: 000162828026010749 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 437.99 million Exact value Exact value: -437987000 USD 2025-01-01 – 2025-12-31: -437987000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Vir Biotechnology, Inc. · 2025-12-31 Vir Biotechnology, Inc. (edgar:1706431) Net Income: -437987000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -437987000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1699446 Filing: 000162828026010749 The citation records this snapshot. The page link may show a newer release later.	−USD 391.78 million Exact value Exact value: -391781000 USD 2025-01-01 – 2025-12-31: -391781000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Vir Biotechnology, Inc. · 2025-12-31 Vir Biotechnology, Inc. (edgar:1706431) Operating Cash Flow: -391781000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -391781000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1197034 Filing: 000162828026010749 The citation records this snapshot. The page link may show a newer release later.	USD 4.83 million Exact value Exact value: 4832000 USD 2025-01-01 – 2025-12-31: 4832000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Vir Biotechnology, Inc. · 2025-12-31 Vir Biotechnology, Inc. (edgar:1706431) Capital Expenditure: 4832000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4832000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1201710 Filing: 000162828026010749 The citation records this snapshot. The page link may show a newer release later.	−USD 396.61 million Calculation and evidence -391781000 − 4832000 USD Exact free cash flow: -396613000 USD 2025-01-01 – 2025-12-31: -391781000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 4832000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Vir Biotechnology, Inc. · 2025-12-31 Vir Biotechnology, Inc. (edgar:1706431) Free cash flow: -396613000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1706431?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -391781000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1197034 Filing: 000162828026010749 Input fundies:CapitalExpenditure: 4832000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm#1201710 Filing: 000162828026010749 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

41 filings · 2,599 latest values · 2,599 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001706431, 1706431, VIR, edgar:1706431

Also known as Vir Biotechnology, Inc.

Vir Biotechnology, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation